DOTA Conjugated JM#21 derivative 7

DOTA-Conjugated JM#21 Derivative 7 (compound Ligand-7) is a CXCR4-targeting peptide derivative conjugated with DOTA, suitable for producing radioligands. Radiolabeled with 177Lu, this compound, referred to as 177Lu-DOTA, demonstrates superior CXCR4 tumor targeting capabilities. In vitro biodistribution studies of 177Lu-DOTA indicate minimal uptake in non-target organs, with the exception of the kidneys.

C([C@H](NC([C@@H](NC([C@@H](NC([C@H]([C@H](CC)C)N)=O)CC(C)C)=O)CCCNC(=N)N)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCCNC(CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O)C(N)=O)=O)CCCCN)=O)CCCNC(=N)N)=O)CO)=O)C=2C=3C(NC2)=CC=CC3